Fairvalue-Calculator Fairvalue-Calculator
EN DE

DIVA Laboratories, Ltd (4153) Fair Value & Analysis

Healthcare · TW · Market cap 1.8B TWD

Price30.00 TWD
Fair Value24.44 TWD
Upside-18.5%
Quality95/100
Evidence: High Range 18.19 TWD – 30.69 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

DIVA Laboratories, Ltd (4153) currently trades at 30.00 TWD, while our model-based Fair Value estimate is 24.44 TWD — implying the stock looks roughly 18.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -34% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is DIVA Laboratories, Ltd (4153) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 24.44 TWD versus a price of 30.00 TWD — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4153?
Our 21-model fair value for DIVA Laboratories, Ltd is 24.44 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 30.00 TWD.
What is the quality score of 4153?
DIVA Laboratories, Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.